A Pilot Phase II Open-Label Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder

Brief description of study

The purpose of this research study is to test whether empagliflozin, a medication part of a group known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, might help reduce symptoms of depression. Since this medication helps the body make metabolites known as ketone bodies which can serve as an alternate energy source for the brain, we can also test whether ketone bodies help with depressed mood. This study was in part motivated by evidence that the “ketogenic diet” might help with mood symptoms, and this medication simulates the effects of a ketogenic diet.

Clinical Study Identifier: s23-00027
Principal Investigator: Dan Iosifescu.
Other Investigator: David Liebers.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.